Background: The International Federation of Gynecology and Obstetrics (FIGO) sys-
provider, 4, 5, 8 a circumstance that may explain the variation in reported prevalence. The manifestations vary from modest to severe disruption of work productivity and quality of life, 10, 11 and increasing maternal morbidity and mortality for pregnant women with pre-existing AUBrelated anemia. 12, 13 In rhagia, and dysfunctional uterine bleeding, which were poorly defined, used internationally in a disparate manner, and had no consistent meaning for the general and academic communities. [15] [16] [17] The second key publication 14 It rapidly became clear that each of these individual causes could require division into subclassifications of cause and phenotype to optimize clinical management and support the broad spectrum of research needed. The subclassification of leiomyomas was an obvious starting point. 14 Three key publications [14] [15] [16] [17] formed the foundation of a simple, flexible, and educationally sound pair of descriptive systems that were designed to provide a quick initial clinical direction of diagnosis and management, but also to be flexible enough to provide effective linkages with laboratory and research aspects.
The present report updates the FIGO recommendations for both FIGO-AUB Systems 1 and 2, including clarifications on terminologies and definitions, as well as modifications in the PALM-COEIN system that include reassignment of some entities, and guidance for subclassification of leiomyomas, much of which has been preliminarily published. [18] [19] [20] These changes represent structured deliberative processes that include use of a modified RAND Delphi process applied to the attendees of a series of FIGO Menstrual Disorders Committee (MDC) sponsored expert meetings. To allow this report to function independently, and to provide context, there exists substantial but necessary overlap with the original publication, 14 and with other subsequent and related publications produced by the MDC since 2011.
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The FIGO MDC is currently working on subclassification systems for adenomyosis and endometrial polyps. The adenomyosis subclassification system is the most advanced and will be published soon in preliminary form with planned validation studies to follow. The polyp system is being developed but a release date has not yet been determined. There is consideration for subclassification systems for AUB-C, -O, -E, and -I, but these initiatives are still in the very early stages of development.
It is important that clinicians recognize that these FIGO systems relate solely to assessment and management of nongestational AUB. There are other causes of genital tract bleeding and urinary tract or gastrointestinal bleeding that do not come from the uterus. These can usually be identified by an appropriate case history and physical examination.
| ACUTE VERSUS CHRONIC NONGESTATIONAL AUB IN THE REPRODUCTIVE YEARS
In the original system, 14 FIGO introduced the concept of nongestational acute AUB in the reproductive years, distinguishing it from chronic AUB-an approach endorsed by the American College of Obstetricians and Gynecologists. 25 These definitions remain unchanged for 2018. Chronic nongestational AUB in the reproductive years is defined as bleeding from the uterine corpus that is abnormal in duration, volume, frequency, and/or regularity, and has been present for the majority of the preceding 6 months. Acute AUB, on the other hand, is defined as an episode of heavy bleeding that, in the opinion of the clinician, is of sufficient quantity to require immediate intervention to minimize or prevent further blood loss. Acute heavy menstrual bleeding may present in the context of existing chronic AUB or can occur in the absence of such a background history.
| FIGO-AUB SYSTEM 1

| Revision of terminologies and definitions of symptoms of abnormal uterine bleeding
The revised FIGO-AUB System 1 is seen in Figure 1 , with changes summarized in Table 1 . As determined by the multinational process described in the original publications, [14] [15] [16] terms such as menorrhagia, metrorrhagia, oligomenorrhea, and dysfunctional uterine bleeding have been abandoned. There is acknowledgement of the specific changes in menstrual bleeding patterns that may be encountered at each end of the reproductive spectrum (i.e. in adolescence or the peri-menopause). In this revision of FIGO AUB System 1, the definition of regularity has been changed from one where the shortest to longest variation is up to 20 days, to variation of 7-9 days, depending upon age (18-25 years ≤9 days; 26-41 years ≤7 days; 42-45 years ≤9 days). 27 For practical purposes, this normal variation in cycle length can be alternatively expressed as ±4 days. Table 2 . The basic/core classification system is almost unchanged and is presented in Figure 2 . There remain the nine main 29, 30 There is some progress regarding the spectrum of two-dimensional ultrasonography findings associated with the diagnosis, 31, 32 but no consensus regarding how many and which of these findings are necessary before there is reasonable certainty that a diagnosis of adenomyosis is present. The eight criteria suggested by the morphological uterus sonographic assessment (MUSA) group are shown in Figure 3 . 31 The FIGO MDC is currently working on an international consensus for an imaging-based adenomyosis classification system designed to phenotype the disorder in a standardized fashion that should facilitate research, education, and clinical care. However, for diagnosis the use of the transvaginal ultrasonography-based MUSA criteria 31 for the diagnosis of adenomyosis for the purposes of FIGO AUB System 2 is suggested.
The only subclassification system ratified so far is the leiomyoma subclassification system, essentially unchanged since the initial 2011 publication 14 (Fig. 4) . The only subtle difference is for Type 3 myomas, where contact with the endometrium is a feature shared by other submucous leiomyomas (Types 0, 1, and 2), whereas intramural location, without focal distortion of the endometrial cavity, is a characteristic of Types 4 and higher. The system now recognizes this area of overlap. It is also recognized that there are some difficulties in applying the leiomyoma subclassification system to the spectrum of leiomyomas that can be encountered, especially in large uteri with multiple leiomyomas. 33 There is now more detailed guidance for distinguishing amongst the leiomyoma subtypes.
Distinguishing between Type 0 and 1, and between Type 6 and 7
leiomyomas is now accomplished by comparing the stalk diameter to T A B L E 1 Summary of changes to FIGO System 1 (normal and abnormal uterine bleeding). T A B L E 2 Summary of changes to FIGO AUB System 2 Causes or Contributors to AUB in the Reproductive Years (PALM-COEIN). F I G U R E 3 Adenomyosis diagnostic criteria. Graphical depictions of the eight TVUS criteria proposed by the MUSA group are presented. These include asymmetrical myometrial thickening (A); myometrial cysts (B); hyperechoic islands (C); fan shaped shadowing (D); echogenic subendometrial lines and buds (E); translesional vascularity (F), where present; irregular junctional zone (G); and an interrupted junctional zone (H). Identification and evaluation of the junctional zone may best be accomplished with three-dimensional ultrasonography. For the present at least, the presence of two or more of these criteria are highly associated with a diagnosis of adenomyosis. Reproduced with permission. ized, then the relationship between the documented myomas and the endometrium should be described using the FIGO classification system.
Parameter Change
Women with AUB and associated malignant or premalignant lesions of the uterus (e.g. endometrial carcinoma, leiomyosarcoma, and atypical endometrial hyperplasia sometimes, referred to as endometrial intraepithelial neoplasia or EIN 34, 35 ), are categorized as having AUB-M. Their categorization is further defined using existent WHO and FIGO classification and staging systems. 36, 37 AUB associated with the use of selected categories of systemic pharmacotherapy or intrauterine systems or devices, is classified as "iatrogenic". 38 In addition to gonadal steroids such as estrogens, progestins, and androgens, and agents that directly affect their production or local function, this category now includes nonsteroidal pharmaceuticals that contribute to ovulatory disorders, such as those that affect dopamine metabolism, including phenothiazines and tricyclic antidepressants. In the original categorization, women with AUB associated with the use of anticoagulants were categorized with coagulopathies (AUB-C); in this revision, they are considered iatrogenic and classified as AUB-I. This includes the modern, non-vitamin-K antagonists such as rivaroxaban that appears to have a greater impact on the volume of menstrual bleeding than the traditional, vitamin K antagonists, typified by warfarin. 39, 40 Category "N", "not otherwise classified" was created in the original system to accommodate entities that are rarely encountered or are ill defined. These include, but are not limited to, entities such as arteriovenous malformations (AVMs) 41 and the lower segment or upper F I G U R E 4 FIGO leiomyoma subclassification system. System 2 classification system including the FIGO leiomyoma subclassification system. The system that includes the tertiary classification of leiomyomas categorizes the submucous group according to the original Wamsteker et al. system 68 and adds categorizations for intramural, subserosal, and transmural lesions. Intracavitary lesions are attached to the endometrium by a narrow stalk (≤10% or the mean of three diameters of the leiomyoma) and are classified as Type 0, whereas Types 1 and 2 require a portion of the lesion to be intramural-with Type 1 being less than 50% of the mean diameter and Type 2 at least 50%. Type 3 lesions are totally intramural but also about the endometrium. Type 3 are formally distinguished from Type 2 with hysteroscopy using the lowest possible intrauterine pressure necessary to allow visualization. Type 4 lesions are intramural leiomyomas that are entirely within the myometrium, with no extension to the endometrial surface or to the serosa. Subserous (Types 5, 6, and 7) leiomyomas represent the mirror image of the submucous leiomyomas-with Type 5 being at least 50% intramural, Type 6 being less than 50% intramural, and Type 7 being attached to the serosa by a stalk that is also ≤10% or the mean of three diameters of the leiomyoma. Classification of lesions that are transmural are categorized by their relationship to both the endometrial and the serosal surfaces. The endometrial relationship is noted first, with the serosal relationship second (e.g. Type 2-5). An additional category, Type 8, is reserved for leiomyomas that do not relate to the myometrium at all, and would include cervical lesions (demonstrated), those that exist in the round or broad ligaments without direct attachment to the uterus, and other so-called "parasitic" lesions. Modified with permission. 67 Abbreviation: FIGO, International Federation of Gynecology and Obstetrics.
cervical niche or "isthmocele" frequently found in association with previous cesarean delivery and sometimes attributed to as a cause of AUB.
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| NOTATION
After the patient has undergone appropriate investigation, discussed below, she could be found to have one or more potential causes of, or contributors to, the AUB symptoms. Consequently, the system has been designed to enable appropriate multi-category notation. While it is recognized that this increased level of complexity will be of most value to specialists and researchers, it should have utility for any healthcare provider.
This approach has been designed following the example of the WHO TNM staging of malignant tumors, with each component addressed for all women investigated for AUB symptoms using the two FIGO AUB Systems. For example, if an individual was suspected to have a disorder of ovulation, a type 2 leiomyoma, and no other anomalies, they would be categorized as follows in the context of a complete
that in clinical practice the use of such full notation might be considered cumbersome, so an option for abbreviation has been developed.
The abbreviated FIGO description of the patient previously described would be AUB-L SM ; -O.
FIGO now encourages clinicians and investigators to consider the use of a matrix for the evaluation of patients with AUB in the reproductive years (Fig. 5 ). This allows for the identification and documentation of the status of the investigation.
| RECOMMENDATIONS FOR CLINICAL INVESTIGATION
A woman presenting with AUB may have one or a number of factors that may contribute to the genesis of the symptoms. Using FIGO AUB System 1 to define the types of AUB symptoms present is a prerequisite to evaluation for the elements in FIGO AUB System 2.
A number of pathological entities (e.g. subserous leiomyoma) may be present that are possibly or even unlikely to be a contributor to the symptoms. Consequently, the investigation of women with AUB during the reproductive years must be undertaken in as comprehensive but practicable fashion given the clinical situation and the available resources, with the findings carefully interpreted for their role in the symptoms. For example, available evidence would suggest that a single 1-cm polyp would not be the cause of the symptom of HMB.
F I G U R E 5 FIGO AUB System 2 diagnostic matrix. A simplified diagnostic matrix is illustrated in the left pane. Each of the primary classification system elements are listed. If a patient has not been completely evaluated for a potential cause it is listed in the "?" column, if evaluation has demonstrated no evidence of the abnormality the "N" column is checked, and if assessment is positive, an X is placed in the appropriate box. An example is shown in the panel on the right. The patient has the symptom of HMB, and interim assessment, including contrast hysterosonography documented in the left matrix has revealed a subserosal leiomyoma designated as L o . However, the patient had a positive historical screening result for coagulopathy and hematological assessments for coagulation disorders are not yet available. Consequently, the "C" and "E" rows remain in the "?" category. The hematological assessment demonstrates that there is no evidence of coagulopathy, so the diagnosis of a primary disorder of endometrial hemostasis is made. The C row can now be assigned an "N" while the E category can be checked as "Y". Abbreviations: AUB, abnormal uterine bleeding; FIGO, International Federation of Gynecology and Obstetrics; HMB, heavy menstrual bleeding.
A suggested approach is illustrated in Figure 6A ,B, and described in brief below.
| General assessment
When evaluating a woman of reproductive age with either acute or chronic genital tract bleeding thought to be AUB, the clinician should ensure that the bleeding is not related to pregnancy, and is emanating from the cervical canal, rather than another location such as the vagina, vulva, perineum, or perianal region. Pregnancy may be reliably confirmed with a urine or serum assay for the presence of the β-subunit of human chorionic gonadotropin (hCG). It is to be noted that determination of the location or viability of a pregnancy is not considered to be within the domain of the FIGO-AUB systems. Women with both acute and chronic AUB should be evaluated for iron deficiency, if possible, with serum ferritin, and for related anemia by measuring hemoglobin and/or hematocrit (preferably a full blood count, including platelets). Once the bleeding has been confirmed, or suspected, to originate in the cervical canal or endometrial cavity, the clinician should systematically evaluate the patient for each of the components of FIGO AUB System 2, the PALM-COEIN classification.
| Determination of ovulatory status
Predictable cyclic menses every 24-38 days are usually (but not always) associated with ovulation whereas bleeding associated with ovulatory disorders is typically irregular in timing and flow, and often interspersed with episodes of amenorrhea.
If, largely based on FIGO AUB System 1, a woman is found to have AUB related to a ovulatory disorder, she is to be categorized as AUB-O. If there is uncertainty regarding ovulatory status, measurement of serum progesterone, timed to the best estimate of mid-luteal phase, may be useful for confirming ovulation in the current cycle.
Whereas endometrial biopsy is not recommended as a method for determination of ovulatory status, when performed and appropriately indicated-to evaluate for the presence of premalignant or malignant endometrial change-histopathological findings reflecting secretory change may confirm that ovulation has occurred.
| Screening for systemic disorders of hemostasis
A structured history is a useful and effective screening tool. FIGO suggests a tool that has been demonstrated to have 90% sensitivity for the detection of these relatively common disorders (coagulopathies) 44 (Table 3) . For those with a positive screening result, further testing is necessary, often following consultation with a physician with a special interest in disorders of coagulation, such as a hematologist. Such tests may include assays for von Willebrand factor, Ristocetin cofactor, partial thromboplastin time (PTT) and other measures. 45 If the results are positive, the woman with AUB would be being categorized as having AUB-C. Previously, by convention, individuals with AUB associated with the use of anticoagulant therapy were categorized as AUB-C, but they now are included in the AUB-I category. [53] [54] [55] There exist a number of techniques for endometrial sampling, but it is important that an adequate sample be obtained before the patient can be considered at low risk for a malignant neoplasm. 56 It is apparent that a relationship exists between chlamydial infection of the endometrium and AUB. Consequently, it may be prudent to consider evaluating for the presence of the organism in symptomatic patients. 57 Although cervical assays seem reasonable, the relationship between cervically obtained specimens and the presence of absence of endometrial infection is unclear. 58 If chronic endometritis is identified, patients should be categorized as having AUB-E.
| Evaluation of the endometrium
| Evaluation of the structure of the endometrial cavity
Evaluation for structural abnormalities affecting the endometrial cavity is performed to identify pathology-including endometrial or endocervical polyps and submucous leiomyomas-that could contribute to AUB. Transvaginal ultrasonography (TVUS) is an appropriate and important screening tool and, in most instances, should be performed early in the course of the investigation. Ideally, the ultrasonography system must be of adequate quality to clearly display both myometrial and endometrial features, and the examiner should have the ability to operate the scanning device and interpret the images displayed.
Regardless, TVUS is not 100% sensitive even in ideal circumstances because polyps and other small lesions may elude detection, even in the context of a normal study.
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(A) (B) FIGURE 6 Investigative algorithms for patients with chronic AUB during the reproductive years. (A) Initial investigation comprises a structured history, physical examination, and the use of appropriate ancillary investigations, in part based upon the history and physical assessment. Evidence suggesting an ovulatory disorder prompts assessment for endocrinopathy, whereas a positive screening result for coagulopathy ( Figure 7 ) will indicate the need for appropriate hematological assessment. A complete blood count should be performed on all women with the symptom of heavy menstrual bleeding. (B) A pragmatic guide to uterine assessment. If the initial evaluation ( Figure 6A ) suggests a low risk for coagulopathy, structural or malignant/premalignant change, patients may be presumed to have AUB-E or -O and offered appropriate treatment options. However, if there is an enhanced risk for endometrial hyperplasia or malignancy (left), endometrial sampling is recommended.
If an adequate specimen is not obtained, hysteroscopic examination and biopsy is recommended. If there is an enhanced risk for a structural abnormality, transvaginal ultrasonography is the next step (right). If evaluation of the endometrium is suboptimal or there is a suggestion of an abnormality affecting the endometrial cavity, either hysteroscopy or contrast hysterosonography is indicated. MRI may be occasionally indicated if hysteroscopy or contrast hysterosonography are not feasible, such as in the case of virginal women. Abbreviations: AUB, abnormal uterine bleeding; MRI, magnetic resonance imaging; TVUS, transvaginal ultrasonography. Images are used courtesy of Malcolm G. Munro. Which of these techniques is used will depend on the resources available to the clinician. [53] [54] [55] In most instances, sonohysterography will be more readily available, particularly when the only available resources for hysteroscopy reside in an operating room. However, if office hysteroscopy is available, there may be additional value, particularly when polyps are suspected, as hysteroscopically directed polypectomy will be feasible in the same setting.
In some parts of the world, notably in the UK (managed by the British National Health Service), there is an emphasis on conducting investigation and management of the symptom of HMB at the first consultation ("One stop management", including key history, examination, transvaginal ultrasonography, and hysteroscopy, if indicated, at the same visit). 28 This type of management has been assisted by the systematic application of the two FIGO AUB Systems -clearly defining the symptoms using FIGO AUB System 1, and then, following an appropriately structured evaluation, categorization of the findings or assessments using FIGO AUB System 2, the PALM-COEIN classification.
When vaginal access is difficult or impossible, a circumstance often encountered with adolescents and virginal women, TVUS, contrast sonohysterography, and office hysteroscopy may not be feasible. In such instances, there is a role for MRI. Alternatively, hysteroscopic examination with indicated biopsies, performed under appropriate anesthesia may be the best approach.
With the PALM-COEIN classification, the presence of a polyp or polyps (AUB-P) is confirmed only with documentation of one or more clearly defined polyps, generally with either hysteroscopy or sonohysterography. Usually, a patient may be categorized with one or more submucous leiomyomas (AUB-L SM ) with either sonohysterography or hysteroscopy. When using either, the clinician should take care to infuse the distending medium with low pressure so that the natural relationships of the leiomyoma with the endometrium and myometrium are distorted. As described above, FIGO now recommends that the distinction between Type 2 and 3 leiomyomas be based upon hysteroscopy performed using the lowest pressure necessary to evaluate these relationships. The use of sonohysterography for this purpose is considered to be a suitable and more practical substitute in a variety of clinical situations.
| Myometrial assessment
For the primary leiomyoma categorization, the myometrium is assessed Tertiary subclassification of leiomyoma type requires that the clinician clarify the relationship of the leiomyomas with the endometrium, endometrial cavity, myometrium, and uterine serosa. At least for those leiomyomas that do not distort the endometrial cavity (Types 3 and up), this distinction requires the use of imaging, either ultrasonography, or, more accurately MRI as described previously.
The myometrium should also be evaluated for the presence of adenomyosis or to distinguish between leiomyomas and localized collections of adenomyosis or adenomyomas. 31, 61 The sonographic and MRI criteria for the diagnosis of adenomyosis are described elsewhere in the present document. While the FIGO MDC is currently developing a system for the classification of adenomyosis, for the present, an assignment of AUB-A is best based on imaging findings consistent with TVUS as described above 31 (Fig. 3) or, if available, using MRI.
30
Although promising for the diagnosis of adenomyosis, the role of both three-dimensional TVUS 62, 63 and sonographic elastography 64, 65 is still a subject of investigation.
If available, MRI may be necessary for evaluation of the myometrium to distinguish between leiomyomas and adenomyosis. MRI imaging may also be superior to TVUS, sonohysterography, and hysteroscopy for measuring the myometrial extent of submucous leiomyomas. 59 However, reliance on MRI is currently impractical, especially for low-resource nations, because of the relative or absolute lack of access within many healthcare systems. to guide the evaluation of women afflicted with chronic AUB, as well as acute AUB once the patient is stabilized (Fig. 7) .
These systems, and their continued and appropriate revision, represent a collaboration involving clinicians, investigators, and other informed participants from six continents. This participation was designed to develop an implementable System 1 and to provide input into the practicality of performing the investigations described for categorizing according to System 2, the PALM-COEIN classification. Currently, the routine characterization of structural lesions of the uterus using MRI is not feasible and its use is not included as a mandatory tool for evaluating patients with chronic AUB. This does not mean that clinicians cannot or should not use MRI if it is deemed necessary and is available, with the results used to categorize leiomyoma type or determine the presence, absence, or location and extent of adenomyosis.
| CONCLUSION
The present paper reports the changes to both FIGO AUB systems based on 6 years of analysis, discussion, and debate since the original publication. The original seminal publications presented effective approaches to the terminologies and definitions around AUB (System 1), followed by development of a novel classification (PALM-COEIN) of underlying causes of abnormal uterine bleeding in the reproductive years (System 2). 14 These developments and refinements are integrated into the whole FIGO-AUB model in this manuscript.
AUTHOR CONTRIBUTIONS
MGM, HODC, and ISF contributed to the development, drafting, and review of the present manuscript.
PARTICIPATING MEMBERS OF THE FIGO MENSTRUAL DISORDERS COMMITTEE, 2015-2018
Rohana This structured history-based instrument is 90% sensitive for the presence of a coagulopathy in women with the symptom of heavy menstrual bleeding. c Patients with a positive screening result should be considered for further evaluation including consultation with a hematologist and/or testing of von Willebrand factor and Ristocetin cofactor.
